[go: up one dir, main page]

US6649353B2 - Method for influencing the p53 linkage to target genes - Google Patents

Method for influencing the p53 linkage to target genes Download PDF

Info

Publication number
US6649353B2
US6649353B2 US09/485,791 US48579100A US6649353B2 US 6649353 B2 US6649353 B2 US 6649353B2 US 48579100 A US48579100 A US 48579100A US 6649353 B2 US6649353 B2 US 6649353B2
Authority
US
United States
Prior art keywords
binding
nucleic acid
acid sequence
target nucleic
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US09/485,791
Other versions
US20030032009A1 (en
Inventor
Wolfgang Willi Deppert
Ella Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of US20030032009A1 publication Critical patent/US20030032009A1/en
Application granted granted Critical
Publication of US6649353B2 publication Critical patent/US6649353B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Definitions

  • the present invention relates to a method for influencing the p53 binding to target genes.
  • p53 is a protein present in animal and human cells and is referred to as a “guardian of the genome.” p53 is a sequence-specific transactivator which is activated in the case of DNA damage. In this form, p53 binds to promoters of target genes and activates the transcription thereof. This causes growth stand-still of the cells and subsequent repair of the DNA damage and cell death, respectively.
  • p53 has lost its transactivator activity in many tumors. This is often due to the fact that the binding of p53 to the promoters of target genes is disturbed or it is not the desired target genes that are regulated.
  • the invention relates to a method for influencing the p53 binding to a target gene, wherein the conformations of p53 and the target gene are coordinated especially by means of conformation modulators and the binding of p53 can be directly or indirectly detected.
  • FIG. 1 shows the DNA conformations of oligonucleotides (SEQ ID NOS: 1-3) which contain on their termini the p53 binding sequence RGC.
  • SEQ ID NO: 2 is in conformation II (i.e., B DNA conformation), while SEQ ID NOS:1 and 3 are in conformation I and III (i.e., non-B DNA conformation).
  • RGC containing oligonucleotides are subjected to an annealing reaction with an oligonucleotide, designated “Lock,” (SEQ ID NO:4) that has complementary sequences to the sequence of the RCG sequences on the termini of SEQ ID NOS:1-3.
  • the autoradiograph of a polyacrylamid gel is shown on which the the various reaction products has been separated.
  • Lanes 2, 4, and 6 show the annealing product of SEQ ID NOS:1, 2, and 3, respectively, with “Lock” (SEQ ID NO:4) where “Lock” was radioactively labeled.
  • Lane 1 shows radioactively labeled “Lock” as control.
  • Lane 8 shows radioactively labeled RCG containing oligonucleotides as control.
  • FIG. 2 shows the DNA binding of p53 to RCG containing oligonucleotides (SEQ ID NOS:1, 2, and 10). Lanes 3 and 4 show binding to RCG 1a/ss (SEQ ID NO:1), lanes 5 and 6 show the binding to RCG 1b/ss (SEQ ID NO:10), and lanes 7 and 8 show the binding to RCG dm/ss (SEQ ID NO:2). Lanes 1 and 2 represent controls.
  • FIG. 3 shows the DNA conformations of oligonucleotides which contain p53 binding sequences of the sequence found by Hupp (SEQ ID NOS:5-6) annealed to Lock-2 (SEQ ID NO:8), and (SEQ ID NO:7) annealed to (SEQ ID NO:9).
  • FIG. 4 shows the DNA binding of p53 to oligonucleotides by p53 binding sequences of the Hupp sequences (SEQ ID NOS:5-7), the oligonucleotides having various DNA conformations.
  • A indicates the absence
  • B the presence of antibody pAb421.
  • the subject matter of the present invention relates to a method of influencing the binding of p53 to a target gene in which the conformations of p53 and the target gene are coordinated, particularly by means of conformation modulators, and the binding of p53 is detected directly or indirectly.
  • the present invention is based on the applicant's insight that p53 binding sequences in the promoters of target genes can be present not only in the “ordinary” B-duplex DNA conformation but also in non-B DNA conformations (e.g., cruciate).
  • non-B DNA conformations e.g., cruciate.
  • the applicant also discovered that p53 identifies its binding sequences in both the B-duplex DNA conformation and in the non-B DNA conformations. However, the identification differs depending on the conformation of p53.
  • these insights are used to influence to binding of p53 to target genes by coordinating the conformations of p53 and the target genes, particularly by means of conformation modulators, and detecting the p53 binding directly or indirectly.
  • p53 comprises a p53 of any kind and origin. It can have a wild-type sequence or be a mutated p53. The latter is preferably a p53 with mutated ability of DNA binding. p53 can also be present in the form of a fragment of p53 which is responsible for the DNA binding. In addition, p53 can be present in the form of a fusion polypeptide. Like any other p53 it can also be present in the form of a vector coding for it.
  • target genes comprises genes of any kind and origin the expression of which is regulated by p53. Examples of such genes are RGC, MCK, mdm2, cyclin G, synthetic p53 reporter genes, p21 and bax, p21 and particularly bax being preferred. p21 is held responsible for the growth stand-still of the cell caused by p53 and bax is held responsible for the cell death caused by p53.
  • the expression “target genes” comprises the promoter sequences thereof and more particularly p53 binding sequences thereof.
  • the target genes may be present in any DNA conformation. They can be present in cells, particularly tumor cells, or occur in isolated fashion. The target genes can also be present in connection with further sequences, particularly with those coding for a reporter protein.
  • the expression “conformation modulators” comprises substances of any kind which can cause a conformational change of a nucleic acid.
  • substances are concerned which can convert a DNA from the B-duplex DNA conformation into a non-B DNA conformation or vice versa. Examples of such substances are intercalating substances.
  • the expression “conformation modulators” also comprises substances of any kind which can effect a conformational change of p53. Examples of such substances are those which can modify the carboxy-terminal regulator region of p53, e.g., antibody pAB 421.
  • direct or indirect detection of p53 binding comprises any detection for such a binding.
  • Examples of a direct detection comprise methods by means of which the p53 binding to DNA can be shown.
  • Indirect detections include methods by means of which it is possible to show the consequences of a p53 DNA binding, e.g., the regulation of the expression of reporter genes and/or biological consequences, such as the growth stand-still of cells or the death thereof.
  • a method according to the invention can be carried out as usual.
  • p53 binding sequences in the B-duplex DNA conformation and in a non-B DNA conformation, respectively can be incubated with p53 and optionally conformation modulators and the DNA binding of p53 is detected directly. It is possible to incubate cells, particularly tumor cells, having disturbed DNA binding of p53 with conformation modulators and upon irradiation of the cells the DNA binding of p53 is detected indirectly via the growth stand-still and the death of the cells, respectively.
  • the present invention it is possible to influence the p53 binding to target genes. This can be used to correct a disturbed DNA binding of p53, which often exists in tumor cells. Furthermore, the DNA binding specificity of p53 can be influenced so as to regulate or control certain desired target genes. Thus, the present invention can be used at least as an accompanying treatment measure to combat tumoral diseases.
  • the present invention also offers the possibility of discovering substances which can be suitable as conformation modulators of p53 and/or its target genes.
  • the method according to the invention is carried out to the effect that in place of known conformation modulators unknown ones are used and the known conformation modulators are optionally used as controls.
  • p53 was isolated as usual from Sf9 insect cells which were infected with recombinant wild type p53-expressing baculoviruses. p53 had a purity of over 80% in an SDS polyacrylamide gel. p53 was used in a binding reaction with oligonucleotides. For preparing these oligonucleotides, the below oligonucleotides were used as a basis:
  • Hu/La-1 Hu/La-2 (SEQ ID NO:5) Hu/La-du SEQ ID NO:7)
  • oligonucleotides contain 1-2 “halfsites” of the p53 binding sequences of RGC and in each case identical terminal sequences at their 5′ ends and 3′ ends.
  • the oligonucleotides were used in an “annealing” reaction with the below oligonucleotide which has complementary sequences with respect to the terminal sequences:
  • Oligonucleotides were obtained which are present in the duplex-B DNA conformation (structure II) and in the non-B DNA conformations, respectively (structures I and III, respectively). See, FIG. 1 . These oligonucleotides were terminally labeled radioactively and used in the binding reaction with p53. The reaction lasted 30 minutes at room temperature. The reaction products were subjected to polyacrylamide gel electrophoresis.
  • p53 was used in a binding reaction with oligonucleotides.
  • the below oligonucleotides were used as a basis:
  • RGC - 1 a/ss SEQ ID NO:1
  • RGC-dm/ss SEQ ID NO:2
  • oligonucleotides contain 1-2 “halfsites” of the p53 binding sequences discovered by Hupp. These p53 binding sequences distinguish themselves in that p53 can bind thereto only after its activation by the antibody PAb 421.
  • the oligonucleotides were used in an “annealing” reaction with the oligonucleotide “lock” indicated in (a). (SEQ ID NO:4). Oligonucleotides were obtained which are present in the duplex-B DNA conformation (Hu/La-du/ds) (SEQ ID NO:7) and in the non-B DNA conformations, respectively (Hu/La-2 (SEQ ID NO:5) and Hu/La-1 (SEQ ID NO:6), respectively). See, FIG. 3 .
  • p53 binds to the oligonucleotides of the three DNA conformations, although to differing degrees.
  • p53 binds to the oligonucleotide in the duplex-B DNA conformation only after the activation of p53 by the PAb 421 antibody, while its binding to non-B DNA conformations takes place without modification of p53. See, FIG. 4 .
  • the binding of PAb 421 to p53 effects an inhibition of the p53 binding to this oligonucleotide in the non-B DNA conformation.
  • the p53 binding to a target gene can be influenced by conformational changes of the target gene and of p53.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Lining Or Joining Of Plastics Or The Like (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Physical Vapour Deposition (AREA)

Abstract

The invention relates to a method for influencing the p53 binding to a target gene, wherein the conformations of p53 and the target gene are coordinated especially by means of conformation modulators and the binding of p53 can be directly or indirectly detected.

Description

This is a national phase filing of the Application No. PCT/DE98/02326, which was filed with the Patent Corporation Treaty on Aug. 7, 1998, and is entitled to priority of the German Patent Application 197 35 221.9, filed Aug. 14, 1997.
I. FIELD OF THE INVENTION
The present invention relates to a method for influencing the p53 binding to target genes.
II. BACKGROUND OF THE INVENTION
p53 is a protein present in animal and human cells and is referred to as a “guardian of the genome.” p53 is a sequence-specific transactivator which is activated in the case of DNA damage. In this form, p53 binds to promoters of target genes and activates the transcription thereof. This causes growth stand-still of the cells and subsequent repair of the DNA damage and cell death, respectively.
It has turned out that p53 has lost its transactivator activity in many tumors. This is often due to the fact that the binding of p53 to the promoters of target genes is disturbed or it is not the desired target genes that are regulated.
Therefore, it is the object of the present invention to provide a product by which it is possible to influence the binding of p53 to target genes.
III. SUMMARY OF THE INVENTION
The invention relates to a method for influencing the p53 binding to a target gene, wherein the conformations of p53 and the target gene are coordinated especially by means of conformation modulators and the binding of p53 can be directly or indirectly detected.
IV. BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows the DNA conformations of oligonucleotides (SEQ ID NOS: 1-3) which contain on their termini the p53 binding sequence RGC. SEQ ID NO: 2 is in conformation II (i.e., B DNA conformation), while SEQ ID NOS:1 and 3 are in conformation I and III (i.e., non-B DNA conformation). To demonstrate the different conformations, RGC containing oligonucleotides are subjected to an annealing reaction with an oligonucleotide, designated “Lock,” (SEQ ID NO:4) that has complementary sequences to the sequence of the RCG sequences on the termini of SEQ ID NOS:1-3. The autoradiograph of a polyacrylamid gel is shown on which the the various reaction products has been separated. Lanes 2, 4, and 6 show the annealing product of SEQ ID NOS:1, 2, and 3, respectively, with “Lock” (SEQ ID NO:4) where “Lock” was radioactively labeled. Lane 1 shows radioactively labeled “Lock” as control. Lane 8 shows radioactively labeled RCG containing oligonucleotides as control.
FIG. 2 shows the DNA binding of p53 to RCG containing oligonucleotides (SEQ ID NOS:1, 2, and 10). Lanes 3 and 4 show binding to RCG 1a/ss (SEQ ID NO:1), lanes 5 and 6 show the binding to RCG 1b/ss (SEQ ID NO:10), and lanes 7 and 8 show the binding to RCG dm/ss (SEQ ID NO:2). Lanes 1 and 2 represent controls.
FIG. 3 shows the DNA conformations of oligonucleotides which contain p53 binding sequences of the sequence found by Hupp (SEQ ID NOS:5-6) annealed to Lock-2 (SEQ ID NO:8), and (SEQ ID NO:7) annealed to (SEQ ID NO:9).
FIG. 4 shows the DNA binding of p53 to oligonucleotides by p53 binding sequences of the Hupp sequences (SEQ ID NOS:5-7), the oligonucleotides having various DNA conformations. (A) indicates the absence, (B) the presence of antibody pAb421.
V. DETAILED DESCRIPTION OF THE INVENTION
It is the object of the present invention to provide a product by which it is possible to influence the binding of p53 to target genes.
According to the invention this is achieved by the subject matters defined in the claims.
Thus, the subject matter of the present invention relates to a method of influencing the binding of p53 to a target gene in which the conformations of p53 and the target gene are coordinated, particularly by means of conformation modulators, and the binding of p53 is detected directly or indirectly.
The present invention is based on the applicant's insight that p53 binding sequences in the promoters of target genes can be present not only in the “ordinary” B-duplex DNA conformation but also in non-B DNA conformations (e.g., cruciate). The applicant also discovered that p53 identifies its binding sequences in both the B-duplex DNA conformation and in the non-B DNA conformations. However, the identification differs depending on the conformation of p53.
According to the invention these insights are used to influence to binding of p53 to target genes by coordinating the conformations of p53 and the target genes, particularly by means of conformation modulators, and detecting the p53 binding directly or indirectly.
The expression “p53” comprises a p53 of any kind and origin. It can have a wild-type sequence or be a mutated p53. The latter is preferably a p53 with mutated ability of DNA binding. p53 can also be present in the form of a fragment of p53 which is responsible for the DNA binding. In addition, p53 can be present in the form of a fusion polypeptide. Like any other p53 it can also be present in the form of a vector coding for it.
The term “target genes” comprises genes of any kind and origin the expression of which is regulated by p53. Examples of such genes are RGC, MCK, mdm2, cyclin G, synthetic p53 reporter genes, p21 and bax, p21 and particularly bax being preferred. p21 is held responsible for the growth stand-still of the cell caused by p53 and bax is held responsible for the cell death caused by p53. In particular, the expression “target genes” comprises the promoter sequences thereof and more particularly p53 binding sequences thereof. The target genes may be present in any DNA conformation. They can be present in cells, particularly tumor cells, or occur in isolated fashion. The target genes can also be present in connection with further sequences, particularly with those coding for a reporter protein.
The expression “conformation modulators” comprises substances of any kind which can cause a conformational change of a nucleic acid. In particular, substances are concerned which can convert a DNA from the B-duplex DNA conformation into a non-B DNA conformation or vice versa. Examples of such substances are intercalating substances. The expression “conformation modulators” also comprises substances of any kind which can effect a conformational change of p53. Examples of such substances are those which can modify the carboxy-terminal regulator region of p53, e.g., antibody pAB 421.
The expression “direct or indirect detection of p53 binding” comprises any detection for such a binding. Examples of a direct detection comprise methods by means of which the p53 binding to DNA can be shown. Indirect detections include methods by means of which it is possible to show the consequences of a p53 DNA binding, e.g., the regulation of the expression of reporter genes and/or biological consequences, such as the growth stand-still of cells or the death thereof.
A method according to the invention can be carried out as usual. For example, p53 binding sequences in the B-duplex DNA conformation and in a non-B DNA conformation, respectively, can be incubated with p53 and optionally conformation modulators and the DNA binding of p53 is detected directly. It is possible to incubate cells, particularly tumor cells, having disturbed DNA binding of p53 with conformation modulators and upon irradiation of the cells the DNA binding of p53 is detected indirectly via the growth stand-still and the death of the cells, respectively.
By means of the present invention it is possible to influence the p53 binding to target genes. This can be used to correct a disturbed DNA binding of p53, which often exists in tumor cells. Furthermore, the DNA binding specificity of p53 can be influenced so as to regulate or control certain desired target genes. Thus, the present invention can be used at least as an accompanying treatment measure to combat tumoral diseases.
The present invention also offers the possibility of discovering substances which can be suitable as conformation modulators of p53 and/or its target genes. For this purpose, the method according to the invention is carried out to the effect that in place of known conformation modulators unknown ones are used and the known conformation modulators are optionally used as controls.
The below examples explain the invention in more detail. The following preparations and examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. The present invention, however, is not limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of the invention only, and methods which are functionally equivalent are within the scope of the invention. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.
VI. EXAMPLES A. Example 1 p53 Binding To A Target Gene
(a) p53 Binding to p53 Binding Sequences of RGC
p53 was isolated as usual from Sf9 insect cells which were infected with recombinant wild type p53-expressing baculoviruses. p53 had a purity of over 80% in an SDS polyacrylamide gel. p53 was used in a binding reaction with oligonucleotides. For preparing these oligonucleotides, the below oligonucleotides were used as a basis:
Hu/La-1
Figure US06649353-20031118-C00001
 		(SEQ ID NO:6)
Hu/La-2
Figure US06649353-20031118-C00002
 		(SEQ ID NO:5)
Hu/La-du
Figure US06649353-20031118-C00003
 		SEQ ID NO:7)
These oligonucleotides contain 1-2 “halfsites” of the p53 binding sequences of RGC and in each case identical terminal sequences at their 5′ ends and 3′ ends. The oligonucleotides were used in an “annealing” reaction with the below oligonucleotide which has complementary sequences with respect to the terminal sequences:
Lock 5′-ccgcggtaccattacctaaggcgtc-3′  (SEQ ID NO:4)
Oligonucleotides were obtained which are present in the duplex-B DNA conformation (structure II) and in the non-B DNA conformations, respectively (structures I and III, respectively). See, FIG. 1. These oligonucleotides were terminally labeled radioactively and used in the binding reaction with p53. The reaction lasted 30 minutes at room temperature. The reaction products were subjected to polyacrylamide gel electrophoresis.
It turned out that p53 binds to the oligonucleotides of the three DNA conformations, although to differing degrees. The strongest bond is found in the case of a non-B DNA conformation (structure I), while the bond to the duplex-B DNA conformation (structure II) and to another non-B DNA conformation (structure III), respectively, is weaker. See, FIG. 2. Thus, it becomes evident that the p53 binding to a target gene can be influenced by a conformational change of the target gene.
(b) p53 Binding to p53 Binding Sequences of the Hupp Sequence
In accordance with the description of (a), p53 was used in a binding reaction with oligonucleotides. For the preparation thereof, the below oligonucleotides were used as a basis:
RGC - 1 b/ss 5′-gacgccttaggtagggccctGGACTTGCCTcccgggatggtaccgcgg-3′ (SEQ ID NO:10)
RGC - 1 a/ss
Figure US06649353-20031118-C00004
 		(SEQ ID NO:1)
RGC-dm/ss
Figure US06649353-20031118-C00005
 		(SEQ ID NO:2)
They contain 1-2 “halfsites” of the p53 binding sequences discovered by Hupp. These p53 binding sequences distinguish themselves in that p53 can bind thereto only after its activation by the antibody PAb 421. The oligonucleotides were used in an “annealing” reaction with the oligonucleotide “lock” indicated in (a). (SEQ ID NO:4). Oligonucleotides were obtained which are present in the duplex-B DNA conformation (Hu/La-du/ds) (SEQ ID NO:7) and in the non-B DNA conformations, respectively (Hu/La-2 (SEQ ID NO:5) and Hu/La-1 (SEQ ID NO:6), respectively). See, FIG. 3.
It turned out that p53 binds to the oligonucleotides of the three DNA conformations, although to differing degrees. p53 binds to the oligonucleotide in the duplex-B DNA conformation only after the activation of p53 by the PAb 421 antibody, while its binding to non-B DNA conformations takes place without modification of p53. See, FIG. 4. On the other hand, the binding of PAb 421 to p53 effects an inhibition of the p53 binding to this oligonucleotide in the non-B DNA conformation. Hence it becomes evident that the p53 binding to a target gene can be influenced by conformational changes of the target gene and of p53.
10 1 58 DNA Artificial Sequence Description of Artificial Sequence p53 binding oligonucleotide RGC-1a/ss 1 gacgccttag gtacctggcc tgcctggact tgcctggcct gcctggatgg taccgcgg 58 2 67 DNA Artificial Sequence Description of Artificial Sequence p53 binding oligonucleotide RGC-dm/ss 2 gacgccttag gtacctgcct ggacttgcct ggtcctccag gcaagtccag gcaggatggt 60 accgcgg 67 3 58 DNA Artificial Sequence Description of Artificial Sequence p53 binding oligonucleotide RGC in conformation III 3 gacgccttag gtacctggac ttgcctggcc tgcctggact tgcctatggt accggcgg 58 4 25 DNA Artificial Sequence Description of Artificial Sequence “Lock” annealing oligonucleotide 4 ccgcggtacc attacctaag gcgtc 25 5 32 DNA Artificial Sequence Description of Artificial Sequence Binding oligonucleotide Hu/La-2 5 gccgccagct tagacatgcc tatcgaccgc cg 32 6 42 DNA Artificial Sequence Description of Artificial SequenceBinding oligonucleotide Hu/La-1 6 gccgccagct tagacatgcc tagacatgcc tatcgaccgc cg 42 7 26 DNA Artificial Sequence Description of Artificial SequenceBinding oligonucleotide Ha/La-du 7 agcttagaca tgcctagaca tgccta 26 8 20 DNA Artificial Sequence Description of Artificial Sequence “Lock-2” annealing oligonucleotide 8 cggcggtcga agctggcggc 20 9 25 DNA Artificial Sequence Description of Artificial Sequence annealing oligonucleotide 9 tcgaatctgt acggatctgt acgga 25 10 48 DNA Artificial Sequence Description of Artificial Sequence p53 binding oligonucleotide RGC-1b/ss 10 gacgccttag gtagggccct ggacttgcct cccgggatgg taccgcgg 48

Claims (15)

What is claimed:
1. A method for identifying a conformation modulator of a p53 target nucleic acid sequence, comprising:
(a) providing a p53 molecule and a p53 target nucleic acid sequence;
(b) exposing said p53 molecule and said p53 target nucleic acid sequence to a candidate substance; and
(c) identifying that said candidate substance is a conformation modulator of a p53 target nucleic acid sequence by comparing binding of said p53 molecule to said p53 target nucleic acid sequence in the presence of said candidate substance to binding of said p53 molecule to said p53 target nucleic acid sequence in the absence of said candidate substance.
2. The method of claim 1, wherein said conformation modulator is a substance that converts the p53 target nucleic acid sequence from B-duplex formation to a non B-duplex formation.
3. The method of claim 1, wherein said conformation modulator is an intercalating substance.
4. The method of claim 1, wherein said p53 target nucleic acid sequence is p21 or bax.
5. The method of claim 1, wherein said p53 molecule is a truncated form of p53, said truncated form of p53 having the ability to bind a p53 target nucleic acid sequence.
6. The method of claim 1, wherein said p53 molecule is a fusion polypeptide.
7. The method of claim 1, wherein binding of said p53 molecule to said p53 target nucleic acid sequence is detected directly.
8. The method of claim 1, wherein binding of said p53 molecule to said p53 target nucleic acid sequence is detected indirectly.
9. The method of claim 1, 2, or 3, wherein said p53 is a mutated p53.
10. The method of claim 1, 2, or 3, wherein said p53 molecule is a wild-type p53 molecule.
11. The method of claim 1, 2, or 3, wherein said p53 target nucleic acid sequence regulates the expression of a synthetic reporter gene.
12. The method of claim 9, wherein said mutation of p53 affects the DNA binding affinity of said mutated p53.
13. The method of claim 9, wherein binding of said p53 molecule to said p53 target nucleic acid sequence is detected by the expression of a reporter gene, wherein said p53 target nucleic acid sequence regulates the expression of said reporter gene.
14. The method of claim 8, wherein binding of said p53 molecule to said p53 target nucleic acid sequence is detected by the biological consequence of p53 binding to said p53 target nucleic acid sequence, wherein said biological consequence is cell growth arrest.
15. The method of claim 1, wherein binding of said p53 molecule to said p53 target nucleic acid sequence is detected by the biological consequence of p53 binding to said p53 target nucleic acid sequence, wherein said biological consequence is cell death.
US09/485,791 1997-08-14 1998-08-07 Method for influencing the p53 linkage to target genes Expired - Fee Related US6649353B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19735221.9 1997-08-14
DE19735221 1997-08-14
DE19735221A DE19735221C1 (en) 1997-08-14 1997-08-14 Influencing the binding of p53 to target genes
PCT/DE1998/002326 WO1999008712A2 (en) 1997-08-14 1998-08-07 METHOD FOR INFLUENCING THE p53 LINKAGE IN TARGET GENES

Publications (2)

Publication Number Publication Date
US20030032009A1 US20030032009A1 (en) 2003-02-13
US6649353B2 true US6649353B2 (en) 2003-11-18

Family

ID=7838941

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/485,791 Expired - Fee Related US6649353B2 (en) 1997-08-14 1998-08-07 Method for influencing the p53 linkage to target genes

Country Status (18)

Country Link
US (1) US6649353B2 (en)
EP (1) EP1015037B1 (en)
JP (1) JP2001514872A (en)
KR (1) KR20010022891A (en)
CN (1) CN1271384A (en)
AT (1) ATE298586T1 (en)
AU (1) AU745612B2 (en)
BR (1) BR9811181A (en)
CA (1) CA2300059A1 (en)
DE (2) DE19735221C1 (en)
HU (1) HUP0002766A3 (en)
ID (1) ID24732A (en)
MX (1) MXPA00001532A (en)
NO (1) NO20000705L (en)
PL (1) PL338889A1 (en)
RU (1) RU2201448C2 (en)
SK (1) SK1812000A3 (en)
WO (1) WO1999008712A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010039013A1 (en) * 1998-03-27 2001-11-08 Levine Arnold L. P53-regulated genes

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201026522A (en) 2009-01-13 2010-07-16 Sdi Corp Power pencil sharper capable of replacing knives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012202A1 (en) * 1992-11-26 1994-06-09 University Of Dundee ACTIVATION OF p53 PROTEIN
WO1997011367A1 (en) 1995-09-18 1997-03-27 Novartis Ag ASSAY FOR IDENTIFYING INHIBITORS OF THE INTERACTION BETWEEN PROTEINS p53 AND dm2
WO1997014794A1 (en) 1995-10-20 1997-04-24 University Of Dundee ACTIVATION OF p53 PROTEIN

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012202A1 (en) * 1992-11-26 1994-06-09 University Of Dundee ACTIVATION OF p53 PROTEIN
WO1997011367A1 (en) 1995-09-18 1997-03-27 Novartis Ag ASSAY FOR IDENTIFYING INHIBITORS OF THE INTERACTION BETWEEN PROTEINS p53 AND dm2
WO1997014794A1 (en) 1995-10-20 1997-04-24 University Of Dundee ACTIVATION OF p53 PROTEIN

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Freifelder (1987) Molecular Biology, 2nd Edition, Jones and Bartlett Publishers, Boston. p. 111.* *
Hainaut et al (1995) Oncogene 10:27-32.* *
Hall et al (1995) Oncogene 10:561-567.* *
Hansen et al., 1996, "Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins," J. Biol. Chem. 271(7):3917-3924.
Kim et al., 1997, "DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53," Oncogene 15(7):857-869 (Published erratum appears in Oncogene, 1997, 15(19):2385.
Luo et al (2000) Nature Biotechnology 18:33-37.* *
Nagaich et al (1997) J. Biol. Chem. 272:14842-14849.* *
Palù et al (1999) J. Biotechnol. 68: 1-13.* *
Verma et al (1997) Nature 389:239-242.* *
White (1996) Genes Dev. 10:1-15.* *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010039013A1 (en) * 1998-03-27 2001-11-08 Levine Arnold L. P53-regulated genes

Also Published As

Publication number Publication date
DE19735221C1 (en) 1999-05-06
HUP0002766A2 (en) 2000-12-28
EP1015037B1 (en) 2005-06-29
JP2001514872A (en) 2001-09-18
CA2300059A1 (en) 1999-02-25
AU9530598A (en) 1999-03-08
NO20000705L (en) 2000-04-13
WO1999008712A2 (en) 1999-02-25
AU745612B2 (en) 2002-03-21
EP1015037A2 (en) 2000-07-05
US20030032009A1 (en) 2003-02-13
WO1999008712A3 (en) 1999-05-14
DE59812900D1 (en) 2005-08-04
ID24732A (en) 2000-08-03
RU2201448C2 (en) 2003-03-27
KR20010022891A (en) 2001-03-26
PL338889A1 (en) 2000-11-20
NO20000705D0 (en) 2000-02-11
BR9811181A (en) 2002-07-02
ATE298586T1 (en) 2005-07-15
CN1271384A (en) 2000-10-25
MXPA00001532A (en) 2002-08-06
SK1812000A3 (en) 2000-08-14
HUP0002766A3 (en) 2003-03-28

Similar Documents

Publication Publication Date Title
Deffie et al. The tumor suppressor p53 regulates its own transcription
Yoon et al. Isolation of two E-box binding factors that interact with the rat tyrosine hydroxylase enhancer
Stahl et al. The simian virus 40 large tumor antigen
Cvekl et al. Transcriptional regulation of the mouse αA-crystallin gene: activation dependent on a cyclic AMP-responsive element (DE1/CRE) and a Pax-6-binding site
Zauberman et al. Sequence‐specific DNA binding by p53: identification of target sites and lack of binding to p53‐MDM2 complexes.
Raycroft et al. Analysis of p53 mutants for transcriptional activity
Virbasius et al. Activation of the human mitochondrial transcription factor A gene by nuclear respiratory factors: a potential regulatory link between nuclear and mitochondrial gene expression in organelle biogenesis.
Xiao et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2
Salinas et al. SUMOylation regulates nucleo-cytoplasmic shuttling of Elk-1
EP1100900B1 (en) Xiap ires and uses thereof
Scocchi et al. The proline-rich antibacterial peptide Bac7 binds to and inhibits in vitro the molecular chaperone DnaK
Cvekl et al. Pax-6 interactions with TATA-box-binding protein and retinoblastoma protein.
US5863757A (en) Transcription factor DP-1
Murata et al. Transcription factor CP2 is essential for lens‐specific expression of the chicken αA‐crystallin gene
Stroeher et al. Alternative RNA splicing that is spatially regulated: generation of transcripts from the Antennapedia gene of Drosophila melanogaster with different protein-coding regions
US6649353B2 (en) Method for influencing the p53 linkage to target genes
Symonds et al. Complex formation between the lymphotropic papovavirus large tumor antigen and the tumor suppressor protein p53
Kanda et al. Stimulation of polyomavirus DNA replication by wild-type p53 through the DNA-binding site
JPH09501567A (en) Novel protein binding to retinoblastoma protein and DNA sequence encoding the same
Rommelaere et al. A method for rapidly screening functionality of actin mutants and tagged actins
US20040147006A1 (en) Peptides that bind to DNA and inhibit DNA replication, and methods of use
Hernández et al. Identification and characterization of the expression of the translation initiation factor 4A (eIF4A) from Drosophila melanogaster
Hovemann et al. The protein Hrb57A of Drosophila melanogaster closely related to hnRNP K from vertebrates is present at sites active in transcription and coprecipitates with four RNA-binding proteins
Long et al. Conserved residues of the bare lymphocyte syndrome transcription factor RFXAP determine coordinate MHC class II expression
Kho et al. The polymyositis-scleroderma autoantigen interacts with the helix-loop-helix proteins E12 and E47

Legal Events

Date Code Title Description
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20071118